Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus

Abstract

Purpose of Review: Infectious diseases contribute significantly to morbidity and mortality in recipients of allogeneic haematopoietic stem cell transplantation (aHSCT), particularly in the era of highly immunosuppressive transplant regimens and alternate donor transplants. Delayed cellular immune recovery is a major mechanism for the increased risk in these patients. Adoptive cell therapy with ex vivo manipulated pathogen-specific T cells (PSTs) is increasingly taking its place as a treatment strategy using donor-derived or third party–banked cells. Recent Findings: The majority of clinical trial data in the form of early-phase studies has been in the prophylaxis or treatment of cytomegalovi..